阿伐曲泊帕治疗儿童持续性及慢性免疫性血小板减少症:3b期试验应答特征的事后分析
该事后分析基于3b期试验(NCT04516967)12周核心期数据,评估阿伐曲泊帕在儿童ITP中的疗效及基线特征和方案剂量调整的影响。阿伐曲泊帕组第15天和第22天累积血小板应答率分别为70.4%和75.9%,安慰剂组均为0%;达到临床有意义应答的患者平均应答时间占比62.5%。方案规定的因血小板>250×10⁹/L而暂停给药可能影响疗效结局。
要点
- 阿伐曲泊帕组第15天和第22天累积血小板应答率分别为70.4%和75.9%,安慰剂组均为0%。
- 92.6%(50/54)接受阿伐曲泊帕治疗的患者达到临床有意义血小板应答,平均应答时间占比62.5%。
- 61.1%患者因血小板>250×10⁹/L发生方案规定暂停给药,可能影响疗效结局。
核心结论
- 阿伐曲泊帕在经重度预处理且难治的儿童ITP人群中,跨临床和人口学亚组均显示临床有意义的血小板应答。
研究设计与样本
- 3b期临床试验(NCT04516967)12周核心期的事后分析,评估基线特征和方案定义剂量调整对应答达成及持续性的影响。
主要发现
- 阿伐曲泊帕组第15天和第22天累积血小板应答率分别为70.4%和75.9%,安慰剂组均为0%。
- 基线特征间仅观察到微小差异。
- 92.6%(50/54)接受阿伐曲泊帕治疗的患者达到临床有意义血小板应答(血小板≥30×10⁹/L),平均应答时间占比62.5%。
- 61.1%患者因血小板>250×10⁹/L发生方案规定暂停给药。
- 78.3%的非持久应答者至少有1次因血小板250-400×10⁹/L而暂停给药,该水平在真实世界临床实践中不会触发暂停给药。
关键数值与推荐
- 血小板应答定义为连续2次血小板计数≥50×10⁹/L。
- 临床有意义血小板应答定义为血小板计数≥30×10⁹/L。
- 方案规定剂量暂停触发阈值为血小板计数>250×10⁹/L。
临床怎么用
- 阿伐曲泊帕在儿童ITP中可快速诱导血小板应答,但方案规定的因血小板>250×10⁹/L暂停给药可能影响疗效评估,真实世界临床中血小板250-400×10⁹/L通常不暂停给药。
局限性
- 事后分析性质,方案规定的剂量暂停可能影响疗效结局,需结合真实世界实践解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12-week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline characteristics and protocol-defined dose adjustments on the achievement and sustainability of response. The cumulative percentage of patients who achieved a platelet response (2 consecutive platelet counts ≥50 × 109/L) by days 15 and 22 was 70.4% and 75.9%, respectively, with avatrombopag (placebo, 0% at both days). Only minor differences were observed by baseline characteristics. Among the 92.6% of patients (50/54) treated with avatrombopag who achieved a clinically meaningful platelet response (platelet count ≥30 × 109/L), the mean percentage of time with response was 62.5%. Protocol-specified dose holds due to a platelet count >250 × 109/L occurred for 61.1% of patients, which may have impacted the efficacy outcomes. 78.3% of non-durable responders had ≥1 dose holds prompted by a platelet count of 250-400 × 109/L, a platelet count that would not prompt a dose hold in real-world clinical practice. Avatrombopag demonstrated a clinically meaningful platelet response across the clinical and demographic subgroups in this heavily pre-treated and refractory paediatric ITP population.
引用
- Grace RF, Leblebisatan G, Aydinok Y, et al. Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial. Br J Haematol. 2026. PMID: 42481135. doi:10.1111/bjh.70709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。